Ionis Pharmaceuticals股票討論區

$Ionis Pharmaceuticals(IONS.US)$
NEWS
“Ionis Pharmaceuticals announces positive Phase 3 results for olezarsen in treating familial chylomicronemia syndrome, showing significant reduction in triglycerides and acute pancreatitis events, potentially offering a breakthrough treatment option.
Results demonstrate olezarsen may represent a novel treatment option for this rare, life-threatening disease, for which there are no approved treatments in the U.S.”

Last week’s PDUFAs:
$Arcutis Biotherapeutics(ARQT.US)$ : Approved 12/15
• ZORYVE® (Roflumilast foam 0.3%)
⇒ topical foam
⇒ PDUFA: 12/16/23
⇒ NDA
⇒ Seborrheic dermatitis
$默沙東(MRK.US)$ : Approved 12/15
• KEYTRUDA (pembrolizumab) + Padcev (enfortumab vedotin-ejfv)
⇒ IV injection
⇒ PDUFA: 05/09/24
⇒ sBLA
⇒ Urothelial cancer
$Glaukos(GKOS.US)$ : Approved 12/14
• iDose® TR (travoprost)
⇒ intracameral implant
⇒ PDUFA: 12/22/23
⇒ NDA
⇒ Glaucoma
$默沙東(MRK.US)$ : Approved ...

The FDA PDUFA Calendar is a chronological calendar of PDUFA target dates as well as Advisory meetings (ADCOMM). PDUFA target dates are dates by which the FDA aims to deliver their decision regarding an NDA or BLA filing. These decisions can however come before the PDUFA target date.
Join us to connect and share, and to get info fast!
$CRISPR Therapeutics(CRSP.US)$$福泰製藥(VRTX.US)$$OptiNose(OPTN.US)$$Arcutis Biotherapeutics(ARQT.US)$$Calliditas Therapeutics(CALT.US)$$bluebird bio(BLUE.US)$$Glaukos(GKOS.US)$$Ionis Pharmaceuticals(IONS.US)$$安進(AMGN.US)$$默沙東(MRK.US)$

Hello mooers, welcome to another week of the FDA calendar. Here are what happened last week and what's coming up this week.
BIGGEST MOVERS FROM THIS WEEK
The CEO of $CNS Pharmaceuticals(CNSP.US)$ has disclosed the acquisition of 15,000 shares at a mean price of $0.69 per share. Shares closed the week down 20% at $1.89.
$Dermata Therapeutics(DRMA.US)$ received FDA approval for its proposed protocols and regulations for the Phase 3 clin...

$Ionis Pharmaceuticals(IONS.US)$營收2019年暴增到11.23億的高點，5年來從5.1億增長到了8.1億，平均增長率爲18%，營業利潤除2019年外均虧損，淨利潤則是由於所得稅返還，在2018和2019年兩年均盈利，其餘3年虧損。
2022前三季度營收增長18%，營業利潤和淨利潤虧損均縮小14%，但依然虧損。
目前看不到甚麼投資價值。